BioSpace News Archive

NeuroRx, Inc announced that it has signed an agreement with GEM Global Yield LLC SCS, the New York based private alternative investment group to provide the NeuroRx with up to HK$ 750 million over a 30 month term following a public listing of NeuroRx’s common stock.

Researchers report that both fluoride and aluminum, individually, are poisonous to the nervous system.

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in Neurology, which suggests that chronic epilepsy may be associated with key measures of sudden cardiac death risk.

Amedisys Inc. (NASDAQ:AMED), a leading independent home health, hospice and personal care company, announced today that after more than 15 years of distinguished service and leadership, including five years as Chairman, Donald A. Washburn is retiring as Chairman of the Board and will not seek reelection at the 2020 Annual Meeting.

Health communication program, supported by Amgen Oncology since 2009, has evolved with innovative tools, including virtual healthcare provider tool in English and Spanish

The report, global proteinuria therapeutics market has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on product and geography for the forecast period 2019-2023.

Medical Group Management Association (MGMA) proudly introduces three new board members, a new board chair and its slate of board members for 2019-2020.

The conference is the largest gathering of clinicians and public health workers, health program managers, policymakers, researchers and advocates working to end the suffering caused by lung disease with a focus specifically on the challenges faced by low-and lower-middle income populations.

State Medicaid Agency Partners with Arine, a Medication-Focused Healthcare Technology Company, to Optimize Medication Use and Improve Patient Health

For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease